secwatch.observer — SEC 8-K summary
======================================

Issuer:     SAB Biotherapeutics, Inc. (SABS)
CIK:        0001833214
Form:       8-K
Filed at:   2024-05-08T23:59:59+00:00
Accession:  0000950170-24-054868
Event type: leadership
Sentiment:  positive
Materiality: 0.40
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SAB Biotherapeutics Appoints Dr. Jay Skyler to Board of Directors
-----------------------------------------------------------------

- Dr. Jay Skyler appointed as Class I director, effective May 3, 2024, to serve until 2025 annual meeting.
- Skyler is Professor of Medicine at University of Miami, former President of American Diabetes Association, and served on boards of DexCom, Amylin, and MiniMed.
- His appointment brings deep Type 1 diabetes expertise to SAB's board, supporting SAB-142 immunotherapy program.
- No material transaction or family relationship with any director or officer; compensation consistent with non-employee directors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1833214/000095017024054868/0000950170-24-054868-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1833214/000095017024054868/sabs-20240503.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-054868

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer